BroadOak Invests in Microsize (Lonza's North American Micronization Business)

BroadOak Leads Acquisition of Particle Dynamics from Edgewater Capital Partners

September 29, 2021

Healthcare Services

Particle Dynamics, a U.S.-based specialist in particle processing and finished-dose manufacturing for pharmaceutical, OTC and nutraceutical customers, was sold by Edgewater Capital Partners to a new investor group led by BroadOak Capital Partners with Research Corporation Technologies and Farragut Capital Partners. The transaction (announced September 29, 2021) creates a new ownership group that aims to accelerate the company’s growth and expand its capabilities at its U.S. GMP, FDA-inspected facilities.

Rockland Immunochemicals Acquires antibodies-online GmbH with financing from BroadOak Capital

February 10, 2022

Biotechnology

Rockland Immunochemicals, a Pennsylvania-based life sciences tools manufacturer, has acquired antibodies-online GmbH, a Germany-based e-commerce marketplace for antibodies and research reagents. BroadOak Capital Partners provided financing to support the transaction, which combines Rockland’s antibody design and manufacturing capabilities with antibodies-online’s e-commerce platform and supplier network to expand capabilities, scale distribution, and strengthen supply-chain stability for research customers worldwide.

Farragut Capital Partners and BroadOak Invest in Particle Dynamics

November 19, 2019

Pharmaceuticals

Farragut Capital Partners led a growth investment in Particle Dynamics, Inc., joined by BroadOak Capital Partners; Particle Dynamics is a portfolio company of Edgewater Capital Partners. The capital will support the company's growth and capability expansion across its particle processing, microencapsulation and finished-dosage manufacturing services operating from FDA‑inspected facilities in St. Louis, Missouri and Seymour, Indiana.

Bain Capital and Cinven to Acquire Lonza Specialty Ingredients

February 8, 2021

Manufacturing

Bain Capital Private Equity and Cinven have entered into definitive agreements to acquire Lonza Specialty Ingredients (LSI), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. LSI, headquartered in Basel, Switzerland, is a global provider of specialty chemicals for microbial control with ~2,800 employees, and the consortium intends to invest in R&D, bolster production capabilities and use LSI as a platform for buy-and-build consolidation in the sector; the transaction was expected to close in H2 2021.

BroadOak Capital Partners Invests Growth Capital in PhenoVista Biosciences

January 18, 2022

Biotechnology

PhenoVista Biosciences, a San Diego–based provider of high-content, imaging-based phenotypic assay services, raised growth capital from BroadOak Capital Partners. The funding will be used to accelerate development of complex biological models (e.g., blood–brain barrier, neurodegenerative disease platforms) and expand PhenoVista's assay and data-analysis capabilities.

Danaher Acquires Precision NanoSystems

June 1, 2021

Biotechnology

Danaher Corporation has acquired Vancouver-based Precision NanoSystems (PNI), a developer of lipid nanoparticle delivery technologies and microfluidic manufacturing platforms for genetic medicines. PNI will join Danaher's Life Sciences platform to expand its capabilities in mRNA and genetic-medicine development and complement existing portfolio companies such as Cytiva and Pall.